Work

Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study

Year: 2025
Type: article
Abstract: Relapsed or refractory osteosarcoma carries a poor prognosis after standard chemotherapy. We conducted a multicenter, randomized, phase II trial (NCT05277480) to compare apatinib plus ifosfamide/etoposide (IE) with IE alone in patients who had progressed following at least one prior line of chemotherapy. Patients were randomized 2:1 to receive apatinib (500 mg orally once daily) plus IE (ifosfamide 1.8 g/m²/day and etoposide 100 mg/m²/day, days 1–3 every 3 weeks) or IE alone (same doses, days 1–5 every 3 weeks). The primary endpoint was progression-free survival (PFS). Between April 14, 2022, and August 22, 2023, 81 patients were enrolled (53 in apatinib plus IE group and 28 in IE group). After a median follow-up of 19.9 months, the median PFS was 5.5 months (95% confidence interval [CI]: 3.9, 6.4) with apatinib plus IE compared with 3.4 months (95% CI: 1.4, 4.6) with IE (hazard ratio, 0.60; 95% CI: 0.37, 0.98; P = 0.0402). The trial met its pre-specified primary endpoint. These results suggest that apatinib plus IE may improve PFS in relapsed or refractory osteosarcoma, but as a randomized phase II study, the findings are exploratory and require confirmation in phase III trials. In patients with metastatic osteosarcoma who have progressed on first-line chemotherapy, the prognosis is poor. Here, the authors report a phase II randomized clinical trial comparing the combination of apatinib (multi tyrosine kinase inhibitor) and chemotherapy (ifosfamide and etoposide) against chemotherapy alone in patients with relapsed or refractory metastatic osteosarcoma.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $6,990
OpenAlex ID: W4416631760
FWCI: 2.211
Cites: 20
Cited by: 6
Related to: 10